Dr Mazzarella meets with ecancer at ASH 2016  to discuss his personal highlights from the conference, with special focus on improved understanding of the biologic factors and diagnostic utility in treating myeloid leukaemias.

Next-generation sequencing in clinical analysis of blood cancers was reported by the group led by Dr Torsten Haferlach in the most recent issue of Blood.

Dr Mazzerella considers how persistence of mutated cells might lead to relapse, to resistance and how randomised trials will shore up these initial investigations into disease clonotypes.

He also highlights mitochondrial exchange between bone marrow cells and cancer cells as a pathway of ongoing research, which may reveal mechanisms behind disease persistence and relapse, and the review of autophagy by Prof Emmanuelle Passegue, available here.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.